Business

Milestone Pharmaceuticals has raised $17 million in a Series B financing round, the company said. According to the company, it will use the money for Phase 2 clinical development of MSP-2017, its intranasal calcium channel… Read more . . .

Russian pharmaceutical company Nativa announced recently that it has partnered with Italian metering valve manufacturer VARI, a subsidiary of the Lindal Group, for development of metered dose inhaler products. The announcement said that the two… Read more . . .

Mylan has launched the Sirdupla salmeterol xinafoate/fluticasone propionate MDI, its bioequivalent version of GlaxoSmithKline’s Seretide (Advair) Evohaler, for the treatment of asthma in the UK, the company announced. The product, which is being marketed in… Read more . . .

PARI Respiratory Equipment has announced that its Kitabis Pak, tobramycin inhalation solution packaged with a PARI LC Plus nebulizer for the treatment of cystic fibrosis, has won a 2015 American Package Design Award, presented by… Read more . . .

The National Heart, Lung, and Blood Institute of the National Institutes of Health has awarded a 3-year, $3 million grant to Pulmotect for clinical studies of its PUL-042 inhaled therapy for the treatment of respiratory… Read more . . .

Generex Biotechnology has announced an agreement with NHTherapeutics to co-develop a formulation of leuprolide for delivery by Generex’s RapidMist buccal aerosol technology. Leuprolide is a gonadotropin-releasing hormone (GnRH) analog which is currently approved at higher… Read more . . .

Danish inhaled drug developer Serendex has announced that it has met a number of milestones this year in preparation for clinical development of its portfolio. According to Serendex, in the first quarter of 2015, the… Read more . . .

Inhaled drug developer Prosonix will be acquired by Circassia Pharmaceuticals for a total of £100 million in cash, the company said. Of that total, £70 million will be paid up front, with an additional £30… Read more . . .

Pharmaxis has announced that beginning in June 2015, Chiesi Farmaceutici will take over the commercialization of the Bronchitol mannitol DPI for the treatment of cystic fibrosis in the UK, Ireland, and Germany. Additionally, Pharmaxis said… Read more . . .